A team of cancer researchers have published research looking at the underlying mechanisms of resistance to the drug, Ibrutinib, which is used to treat patients with mantle cell lymphoma.
A team of cancer researchers have published research looking at the underlying mechanisms of resistance to the drug, Ibrutinib, which is used to treat patients with mantle cell lymphoma.